Athenex (ATNX) Stock Price
Athenex Price
Revenue has compounded at 74.2% per year over the past 8 years to 102.82 M USD. Athenex's net margin stands at -96.3%, up from -131.8% several years earlier. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
Athenex stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Athenex business model & stock analysis
Frequently asked questions about Athenex
Athenex Inc is a pharmaceutical company based in the United States. It was founded in 2003 by Dr. Johnson Lau and Dr. Rudolf Kwan. The company specializes in the discovery, development, and commercialization of innovative oncology drugs. Athenex Inc has a diverse pipeline of products, including oral chemotherapy drugs, immunotherapy agents, and targeted therapies. The company has strategic partnerships with various institutions, including the Buffalo Medical Innovation and Commercialization Hub, which aids in the development and manufacturing of its products. With a strong focus on research and development, Athenex Inc continues to strive towards improving treatment options for cancer patients.
The business model of Athenex Inc revolves around the development and commercialization of innovative therapies for cancer treatment. The company focuses on both oral and injectable oncology drugs that address unmet medical needs. Athenex employs a vertically integrated approach, combining its research and development capabilities with manufacturing and commercialization expertise. By leveraging its proprietary technology platforms, including Orascovery and Src Kinase Inhibition, Athenex aims to enable more effective and targeted cancer treatments. This strategic model allows the company to bring novel therapies to market more efficiently and broaden its product portfolio, ultimately improving patient outcomes.
Athenex Inc is primarily active in the biopharmaceutical and oncology industries. The company focuses on the development and commercialization of innovative therapies to treat cancer and other diseases. Athenex is committed to advancing medical science and improving patient outcomes through its research and development efforts. With its expertise in the field, Athenex aims to provide effective and safe treatment options for patients globally.
The main competitors of Athenex Inc in the market are pharmaceutical companies such as AstraZeneca, Pfizer, and Novartis.
Athenex Inc. has achieved several significant milestones in its operations. The company received FDA approval for its oral paclitaxel and encequidar in metastatic breast cancer, providing a new treatment option for patients. Athenex Inc. also secured a strategic partnership with Almirall to commercialize and develop its KX2-391 and KX-01 drugs for the treatment of actinic keratosis and cutaneous squamous cell carcinoma. Furthermore, the company witnessed the successful completion of a Phase III study on oral paclitaxel in gastric cancer, demonstrating positive outcomes. These milestones showcase Athenex Inc.'s dedication to advancing innovative treatments and expanding its therapeutic portfolio.
Athenex Inc is primarily present in the United States and various regions within Asia. The company has a strong presence in China, often referred to as its core market, where it operates multiple facilities and has established partnerships. Additionally, Athenex Inc has a significant presence in other Asian countries and regions such as Japan, Korea, and Southeast Asia. With its focus on developing and commercializing innovative oncology and immune-oncology products, Athenex Inc continues to expand its global footprint while maintaining a solid presence in the United States and key Asian markets.
Athenex Inc represents a commitment to innovation, integrity, and patient-centered care. The company aims to develop and deliver innovative therapies to improve the lives of patients around the world. With a strong focus on research and development, Athenex Inc prioritizes groundbreaking solutions in the fields of oncology and immunology. Their corporate philosophy emphasizes collaboration, excellence, and a passion for scientific advancements. By harnessing cutting-edge technologies and fostering strategic partnerships, Athenex Inc strives to address unmet medical needs and make a positive impact in the healthcare industry.
9 analysts currently rate the Athenex stock: 6 recommend buying, 3 holding and 0 selling.
The Athenex share (ATNX) is listed on 4 stock exchanges, including: NASDAQ (ATNX), Frankfurt (2MT.F), München (2MT.MU), Düsseldorf (2MT.DU).
Athenex Inc. is an American biopharmaceutical company specializing in the development and manufacture of innovative drugs for cancer and other diseases. Athenex has various divisions focusing on research and development, pharmaceutical manufacturing, marketing and sales, and biopharmaceutical services. The company uses novel technologies and scientific knowledge in the development of its drugs and has several medications in clinical trials, including oral cancer drugs and specialized antibiotics. Athenex operates state-of-the-art manufacturing facilities in the U.S. and China, producing a wide range of pharmaceuticals. Its marketing and sales team distributes medications for cancer treatments and other diseases both domestically and internationally through strategic partnerships, direct sales, and online platforms. Additionally, Athenex offers biopharmaceutical services such as drug development, clinical trials, analysis, manufacturing, and quality assurance for other companies. The company's product offerings include oncology drugs, immunotherapies, and specialized antibiotics aimed at improving the lives of cancer patients, boosting treatment outcomes, combating antibiotic resistance, and developing new drugs for antibiotic-resistant bacteria strains. Athenex has a strong business model built on years of industry experience and a portfolio of innovative products and services, with a focus on meeting the needs of patients, doctors, and other stakeholders. The company will continue to invest in research and development to enhance its products and services and ensure future growth.
The revenue cannot currently be calculated for Athenex.
The profit cannot currently be calculated for Athenex.
The P/E ratio cannot be calculated for Athenex at the moment.
The P/S cannot be calculated for Athenex currently.
The Eulerpool Quality Score for Athenex is 2/10.
The ISIN of Athenex is US04685N1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Athenex is A2DTE9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Athenex is ATNX. The ticker symbol is used to trade Athenex shares on the stock exchange.
Athenex stock
Athenex Ticker
Athenex FIGI
All fundamentals and in-depth analysis of Athenex
Our stock analysis for Athenex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athenex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.